- Home
- Publications
- Publication Search
- Publication Details
Title
Directing the use of DDR kinase inhibitors in cancer treatment
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 26, Issue 12, Pages 1341-1355
Publisher
Informa UK Limited
Online
2017-10-06
DOI
10.1080/13543784.2017.1389895
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Modeling Therapy Resistance in BRCA1/2 -Mutant Cancers
- (2017) Amy Dréan et al. MOLECULAR CANCER THERAPEUTICS
- RAD51 interconnects between DNA replication, DNA repair and immunity
- (2017) Souparno Bhattacharya et al. NUCLEIC ACIDS RESEARCH
- PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma
- (2017) V Colicchia et al. ONCOGENE
- PARP inhibitors: Synthetic lethality in the clinic
- (2017) Christopher J. Lord et al. SCIENCE
- Targeting the ATR-CHK1 Axis in Cancer Therapy
- (2017) Stuart Rundle et al. Cancers
- PARP inhibitor combination therapy
- (2016) Amy Dréan et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Genetically engineered mouse models in oncology research and cancer medicine
- (2016) Kelly Kersten et al. EMBO Molecular Medicine
- Phase II evaluation of LY2603618, a first-generation CHK1 inhibitor, in combination with pemetrexed in patients with advanced or metastatic non-small cell lung cancer
- (2016) Giorgio Scagliotti et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months
- (2016) Suzanne Leijen et al. JOURNAL OF CLINICAL ONCOLOGY
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- PAXIP1 Potentiates the Combination of WEE1 Inhibitor AZD1775 and Platinum Agents in Lung Cancer
- (2016) Ankita Jhuraney et al. MOLECULAR CANCER THERAPEUTICS
- A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors
- (2016) Sergio Ruiz et al. MOLECULAR CELL
- ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
- (2016) Chris T. Williamson et al. Nature Communications
- A synthetic lethal screen identifies ATR-inhibition as a novel therapeutic approach for POLD1-deficient cancers
- (2016) Sandra Hocke et al. Oncotarget
- Efficacy of ATR inhibitors as single agents in Ewing sarcoma
- (2016) Maria Nieto-Soler et al. Oncotarget
- Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck
- (2016) Kie Kyon Huang et al. Scientific Reports
- Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities
- (2016) Kumar Sanjiv et al. Cell Reports
- Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer
- (2016) Eileen E. Parkes et al. JNCI-Journal of the National Cancer Institute
- DNA Damage Response and Immune Defense: Links and Mechanisms
- (2016) Rania Nakad et al. Frontiers in Genetics
- Cancer Cells with Alternative Lengthening of Telomeres Do Not Display a General Hypersensitivity to ATR Inhibition
- (2016) Katharina I. Deeg et al. Frontiers in Oncology
- WEE1 inhibition in pancreatic cancer cells is dependent on DNA repair status in a context dependent manner
- (2016) Shruti Lal et al. Scientific Reports
- ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells
- (2015) M. Kwok et al. BLOOD
- Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
- (2015) Gry Irene Magnussen et al. BMC CANCER
- Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation
- (2015) Sophia X. Pfister et al. CANCER CELL
- Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer
- (2015) Guan Wang et al. CANCER LETTERS
- A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer
- (2015) Felix Dietlein et al. CELL
- Molecular Pathways: Targeting ATR in Cancer Therapy
- (2015) L. M. Karnitz et al. CLINICAL CANCER RESEARCH
- Phase I Study of Single-Agent AZD1775 (MK-1775), a Wee1 Kinase Inhibitor, in Patients With Refractory Solid Tumors
- (2015) Khanh Do et al. JOURNAL OF CLINICAL ONCOLOGY
- The core spliceosome as target and effector of non-canonical ATM signalling
- (2015) Maria Tresini et al. NATURE
- REV7 counteracts DNA double-strand break resection and affects PARP inhibition
- (2015) Guotai Xu et al. NATURE
- Involvement of ATM in homologous recombination after end resection and RAD51 nucleofilament formation
- (2015) A. Bakr et al. NUCLEIC ACIDS RESEARCH
- ATM and ATR as therapeutic targets in cancer
- (2015) Anika Maria Weber et al. PHARMACOLOGY & THERAPEUTICS
- The DNA-dependent protein kinase: A multifunctional protein kinase with roles in DNA double strand break repair and mitosis
- (2015) Nicholas Jette et al. PROGRESS IN BIOPHYSICS & MOLECULAR BIOLOGY
- Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors
- (2015) R. L. Flynn et al. SCIENCE
- Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors
- (2015) Yizhu Li et al. Oncotarget
- Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736
- (2015) Valentina Restelli et al. Oncotarget
- A subset of cancer cell lines is acutely sensitive to the Chk1 inhibitor MK-8776 as monotherapy due to CDK2 activation in S phase
- (2015) Nandini Sakurikar et al. Oncotarget
- A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments
- (2015) Kareem N. Mohni et al. PLoS One
- Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma
- (2015) Rosaria Chilà et al. Oncotarget
- γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
- (2014) Rebecca Rawlinson et al. BMC CANCER
- Identification of synthetic lethality of PRKDC in MYC-dependent human cancers by pooled shRNA screening
- (2014) Zongxiang Zhou et al. BMC CANCER
- Chk1 Inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers
- (2014) Christopher Bryant et al. BMC CANCER
- Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors
- (2014) Edward Sausville et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- ATR Inhibitors VE-821 and VX-970 Sensitize Cancer Cells to Topoisomerase I Inhibitors by Disabling DNA Replication Initiation and Fork Elongation Responses
- (2014) R. Josse et al. CANCER RESEARCH
- ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency
- (2014) K. N. Mohni et al. CANCER RESEARCH
- Depletion of ATR selectively sensitizes ATM-deficient human mammary epithelial cells to ionizing radiation and DNA-damaging agents
- (2014) Yuxia Cui et al. CELL CYCLE
- Replication stress and cancer: It takes two to tango
- (2014) Emilio Lecona et al. EXPERIMENTAL CELL RESEARCH
- Preclinical analyses and phase I evaluation of LY2603618 administered in combination with Pemetrexed and cisplatin in patients with advanced cancer
- (2014) Emiliano Calvo et al. INVESTIGATIONAL NEW DRUGS
- Identification of Wee1 as a novel therapeutic target for mutant RAS-driven acute leukemia and other malignancies
- (2014) E Weisberg et al. LEUKEMIA
- Wee-1 Kinase Inhibition Overcomes Cisplatin Resistance Associated with High-Risk TP53 Mutations in Head and Neck Cancer through Mitotic Arrest Followed by Senescence
- (2014) A. A. Osman et al. MOLECULAR CANCER THERAPEUTICS
- CHK2 kinase in the DNA damage response and beyond
- (2014) L. Zannini et al. Journal of Molecular Cell Biology
- A Functional Cancer Genomics Screen Identifies a Druggable Synthetic Lethal Interaction between MSH3 and PRKDC
- (2014) F. Dietlein et al. Cancer Discovery
- ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status
- (2013) C. J. Huntoon et al. CANCER RESEARCH
- ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation
- (2013) L. Biddlestone-Thorpe et al. CLINICAL CANCER RESEARCH
- Checkpoint blocking antibodies in cancer immunotherapy
- (2013) Chrisann Kyi et al. FEBS LETTERS
- CHK1 and WEE1 inhibition combine synergistically to enhance therapeutic efficacy in acute myeloid leukemia ex vivo
- (2013) L. Chaudhuri et al. HAEMATOLOGICA
- Roles of Chk1 in cell biology and cancer therapy
- (2013) Youwei Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity
- (2013) Kevin M. Foote et al. JOURNAL OF MEDICINAL CHEMISTRY
- Preclinical Evaluation of a Novel ATM Inhibitor, KU59403, In Vitro and In Vivo in p53 Functional and Dysfunctional Models of Human Cancer
- (2013) M. A. Batey et al. MOLECULAR CANCER THERAPEUTICS
- Preclinical Evaluation of the WEE1 Inhibitor MK-1775 as Single-Agent Anticancer Therapy
- (2013) A. D. Guertin et al. MOLECULAR CANCER THERAPEUTICS
- Signatures of mutational processes in human cancer
- (2013) Ludmil B. Alexandrov et al. NATURE
- Causes and consequences of replication stress
- (2013) Michelle K. Zeman et al. NATURE CELL BIOLOGY
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy
- (2013) Cigall Kadoch et al. NATURE GENETICS
- The ATM protein kinase: regulating the cellular response to genotoxic stress and more
- (2013) Yosef Shiloh et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- Landscape of somatic mutations and clonal evolution in mantle cell lymphoma
- (2013) S. Bea et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Therapeutic Targeting of a Robust Non-Oncogene Addiction to PRKDC in ATM-Defective Tumors
- (2013) A. Riabinska et al. Science Translational Medicine
- The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy
- (2012) Remko Prevo et al. CANCER BIOLOGY & THERAPY
- Combined inhibition of Chk1 and Wee1: In vitro synergistic effect translates to tumor growth inhibition in vivo
- (2012) Laura Carrassa et al. CELL CYCLE
- Phase I and Pharmacologic Trial of Cytosine Arabinoside with the Selective Checkpoint 1 Inhibitor Sch 900776 in Refractory Acute Leukemias
- (2012) J. E. Karp et al. CLINICAL CANCER RESEARCH
- Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53
- (2012) Chris T. Williamson et al. EMBO Molecular Medicine
- DNA-PKcs Expression Predicts Response to Radiotherapy in Prostate Cancer
- (2012) Patrick Bouchaert et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- The DNA damage response and cancer therapy
- (2012) Christopher J. Lord et al. NATURE
- Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation
- (2012) E Fokas et al. Cell Death & Disease
- Forced Mitotic Entry of S-Phase Cells as a Therapeutic Strategy Induced by Inhibition of WEE1
- (2012) Marieke Aarts et al. Cancer Discovery
- Identification and evaluation of a potent novel ATR inhibitor, NU6027, in breast and ovarian cancer cell lines
- (2011) A Peasland et al. BRITISH JOURNAL OF CANCER
- CCT241533 Is a Potent and Selective Inhibitor of CHK2 that Potentiates the Cytotoxicity of PARP Inhibitors
- (2011) Victoria E. Anderson et al. CANCER RESEARCH
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents
- (2011) Jean-Damien Charrier et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR
- (2011) Philip M Reaper et al. Nature Chemical Biology
- A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations
- (2011) Luis I Toledo et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
- (2011) A. G. Patel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanism of Radiosensitization by the Chk1/2 Inhibitor AZD7762 Involves Abrogation of the G2Checkpoint and Inhibition of Homologous Recombinational DNA Repair
- (2010) Meredith A. Morgan et al. CANCER RESEARCH
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- New Insights into Checkpoint Kinase 1 in the DNA Damage Response Signaling Network
- (2010) Y. Dai et al. CLINICAL CANCER RESEARCH
- Structure-Based Design of Potent and Selective 2-(Quinazolin-2-yl)phenol Inhibitors of Checkpoint Kinase 2
- (2010) John J. Caldwell et al. JOURNAL OF MEDICINAL CHEMISTRY
- ATM Deficiency Sensitizes Mantle Cell Lymphoma Cells to Poly(ADP-Ribose) Polymerase-1 Inhibitors
- (2010) C. T. Williamson et al. MOLECULAR CANCER THERAPEUTICS
- Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86
- (2009) C Beskow et al. BRITISH JOURNAL OF CANCER
- DNA-PKcs deficiency in human: long predicted, finally found
- (2009) Mirjam van der Burg et al. Current Opinion in Allergy and Clinical Immunology
- Bleomycin-induced over-replication involves sustained inhibition of mitotic entry through the ATM/ATR pathway
- (2009) Yuji Nakayama et al. EXPERIMENTAL CELL RESEARCH
- Cellular Inhibition of Checkpoint Kinase 2 (Chk2) and Potentiation of Camptothecins and Radiation by the Novel Chk2 Inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid -amide]
- (2009) A. G. Jobson et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion
- (2009) S. E. Golding et al. MOLECULAR CANCER THERAPEUTICS
- Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents
- (2009) H. Hirai et al. MOLECULAR CANCER THERAPEUTICS
- The DNA-damage response in human biology and disease
- (2009) Stephen P. Jackson et al. NATURE
- Cyclin B1 is an efficacy-predicting biomarker for Chk1 inhibitors
- (2008) Zhan Xiao et al. BIOMARKERS
- AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies
- (2008) S. D. Zabludoff et al. MOLECULAR CANCER THERAPEUTICS
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
- Resistance to therapy caused by intragenic deletion in BRCA2
- (2008) Stacey L. Edwards et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More